---
document_datetime: 2023-09-21 20:13:26
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zoledronic-acid-medac-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: zoledronic-acid-medac-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.5998043
conversion_datetime: 2025-12-17 22:17:01.965373
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
EMA/626529/2020

## Zoledronic acid medac

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0030              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 23/09/2020                          |                                             | SmPC, Annex II, Labelling and PL |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| IB/0029/G          | This was an application for a group of variations. B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s) C.I.7.a - Deletion of - a pharmaceutical form                                                                                                                                                                                                                                                      | 10/06/2020 | 17/09/2020 | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/3149/ 201908 | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)                                                                                                                                                                                                                                                                                                                                          | 17/04/2020 | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0027/G          | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                          | 09/12/2019 | n/a        |                                  |                                   |
| IB/0025/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 24/09/2019 | 17/09/2020 | Annex II and PL                  |                                   |

<div style=\"page-break-after: always\"></div>

| material/intermediate B.II.b.1.f - Replacement manufacturing site for part manufacturing process manufacturing operation(s) release, batch control, sterile medicinal products aseptically manufactured) immunological medicinal B.II.b.2.a - Change to importer, arrangements and quality Replacement/addition of control/testing takes place B.II.b.3.z - Change in the the finished or intermediate B.II.b.4.b - Change in the size ranges) of the finished down to 10-fold B.II.b.5.b - Change to in-process applied during the manufacture product - Addition of a B.II.b.5.b - Change to in-process applied during the manufacture product - Addition of a B.II.b.5.z - Change to in-process applied during the manufacture product - Other variation B.II.b.5.z - Change to in-process applied during the manufacture product - Other variation B.II.d.2.d - Change in test   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |                           |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------|
| IB/0026/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 31/07/2019 | n/a | specification limits      |
| IB/0024/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 26/06/2019 | n/a | B.I.c.2.b - Change in the |

<div style=\"page-break-after: always\"></div>

|                    | and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                |            |            |                                  |                                                                                                                                                                                                                                    |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/3149/ 201808 | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)                                                                                                                                                                                                                                                                                                    | 11/04/2019 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                  |
| IA/0022            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                         | 31/05/2018 | n/a        |                                  |                                                                                                                                                                                                                                    |
| PSUSA/3149/ 201708 | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)                                                                                                                                                                                                                                                                                                    | 12/04/2018 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                  |
| IAIN/0021/G        | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 16/03/2018 | n/a        |                                  |                                                                                                                                                                                                                                    |
| PSUSA/3149/ 201608 | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)                                                                                                                                                                                                                                                                                                    | 21/04/2017 | 16/06/2017 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3149/201608.                                                                                          |
| R/0018             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                               | 23/02/2017 | 28/04/2017 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Zoledronic acid medac in the approved indication remains favourable and therefore recommended the renewal of the |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                          |            |            |             | marketing authorisation with unlimited validity.                                                                                          |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0016          | B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR                                                                                                                           | 26/07/2016 | n/a        |             |                                                                                                                                           |
| PSUSA/3149/ 201508 | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)                                                                                                                                                                                                                       | 28/04/2016 | 29/06/2016 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3149/201508. |
| IB/0015/G          | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code A.7 - Administrative change - Deletion of manufacturing sites B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) | 27/05/2016 | 28/04/2017 | SmPC and PL |                                                                                                                                           |
| IAIN/0013          | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                           | 02/12/2015 | 29/06/2016 | SmPC and PL |                                                                                                                                           |
| IA/0012            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                             | 27/11/2015 | n/a        |             |                                                                                                                                           |
| IB/0010            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                               | 11/11/2015 | n/a        |             |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                    | authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        |                                                                                                                                           |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0011          | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 21/10/2015 | 29/06/2016 | SmPC, Labelling and PL |                                                                                                                                           |
| PSUSA/3149/ 201408 | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 23/04/2015 | 03/07/2015 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3149/201408. |
| IAIN/0009          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/04/2015 | n/a        |                        |                                                                                                                                           |
| IB/0007/G          | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing | 22/12/2014 | 03/07/2015 | Annex II and PL        |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |              |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------|
| IA/0006/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 10/04/2014 | n/a | manufacturer |

<div style=\"page-break-after: always\"></div>

| PSUSA/3149/ 201308   | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)                                                                                                                                                           | 10/04/2014   | n/a        |                       | PRAC Recommendation - maintenance   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-------------------------------------|
| IB/0005              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 15/01/2014   | 15/01/2015 | SmPC and PL           |                                     |
| IB/0003              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH               | 16/07/2013   | 03/12/2013 | SmPC, Annex II and PL |                                     |
| IB/0002              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH               | 14/12/2012   | 03/12/2013 | SmPC and PL           |                                     |
| IAIN/0001            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                            | 14/12/2012   | 03/12/2013 | Annex II and PL       |                                     |